News
A New Impulse for Families: Webinar on Nutritional Education in PKU on February 23, 2026
12 Feb 2026
Following a successful start at ESPKU 2025, we are continuing our initiative on nutritional education in PKU. The kick‑off event already attracted interest among the participants — thanks in large part to the inspiring contributions of our three speakers Tina Eisenblätter (Diplom‑Psychologist), Vanessa Korpel (Dietitian) and Elias Hoffjann (Dietitian).
The focus was on how children with PKU can be supported [...]
Webinar: Medical Rehabilitation for PKU
16 Jan 2026
POA Pharma is starting the year 2026 with a special online webinar dedicated to a frequently underestimated topic: medical rehabilitation for phenylketonuria (PKU).
For many people with PKU, rehabilitation is an important step toward stabilizing their long-term health and improving their quality of life. However, in practice, various challenges often arise. Rehabilitation applications are not...
POA Pharma GmbH Announces 2025 Medical Nutrition Scholarship Winners
21 Nov 2025
At POA we are proud to announce the recipients of the 2025 Medical Nutrition Scholarship as Lina-Josefine Gruhn and Hanna Storz, who will each receive:
- A grant of up to €2,500 to support their studies or training courses.
- A technology package valued at up to €2,000 to assist with digital learning.
The POA [...]
POA Pharma GmbH announces Medical Nutrition Scholarship Winners for 2024
25 Oct 2024
POA Pharma GmbH, a pharmaceutical company based in Sprockhövel, successfully ran its Medical Nutrition Scholarship for the second year. This year, the scholarship extended the applicant pool to Austria and the German Market. The award, which was created by POA Pharma’s parent company, Galen Ltd, aims to support people across Europe with metabolic disorders, such...
POA Pharma announces expansion into Austria, deepening its inborn metabolic disease footprint in Europe
30 May 2024
POA Pharma Scandinavia AB, a speciality pharmaceutical company with expertise across multiple therapeutic areas, has today announced the launch of PKU Easy Microtabs Plus in Austria.
This marks the latest milestone for POA Pharma, as it continues to expand its European footprint in the inborn metabolic disease (IMD) market, after launching the product in Germany [...]
POA Pharma Interview with Hamburger Kaffeeklatsch’s Johannes Röhr
15 Mar 2024
In the March 2024 issue of the German PKU related newspaper 'Hamburger Kaffeeklatsch', Johannes Röhr interviews POA Pharma about its company mission and PKU EASY Microtabs. For a German version of the interview, click here.
POA Pharma GmbH announces Germany’s Medical Nutrition Scholarship Winners for 2023
19 Oct 2023
POA Pharma GmbH, a speciality pharmaceutical company based in Sprockhövel, has announced the winners of its Medical Nutrition Scholarship Award for 2023 as Emilie Göllner and Kim Hamberger.
The award, which was created by POA Pharma’s parent company, Galen Ltd, aims to support people across Europe with metabolic disorders, such as Phenylketonuria (PKU) and Tyrosinemia (TYR), [...]
POA Pharma GmbH announces the launch of PKU Easy Microtabs Plus into the German Market
11 Oct 2023
POA Pharma GmbH, the privately-owned pharmaceutical sales and marketing company, has today announced the launch of PKU Easy Microtabs Plus in Germany.
PKU Easy Microtabs Plus, which are specifically for individuals with Phenylketonuria (PKU), mark POA Pharma GmbH’s entry into the inborn metabolic disease (IMD) market.
The new PKU EASY Microtabs Plus product provides...
POA Pharma announces launch of activities in Germany
20 Apr 2023
POA Pharma Scandinavia AB, a speciality pharmaceutical company with expertise across multiple therapeutic areas, has today announced its expansion into Germany as POA Pharma GmbH.
POA Pharma, headquartered in Copenhagen with additional facilities located across the Nordic region, is part of Galen Limited. This privately owned company, which was established in 1968, has global headquarters [...]
POA Pharma enters the German market securing exclusive in-licensing rights for Rapilose® Oral Glucose Solution (OGS)
19 Sep 2022
POA Pharma Scandinavia AB, a Galen Limited owned company, has announced its entry into the German market, securing an exclusive in-licensing agreement with Penlan Healthcare Limited for Rapilose® OGS.
POA Pharma’s parent company, Galen Limited, a global pharmaceutical company, and proud member of the Almac Group, has an existing, long standing in-licensing relationship with Penlan...
Galen Medical Nutrition Announces Scholarship Award is open for applications
26 Jul 2021
Supporting patients with metabolic disorders accessing further education
Craigavon, U.K. – 27 Jul 2021 - Galen, the privately-owned pharmaceutical sales and marketing company, is pleased to announce the inaugural Galen Medical Nutrition Scholarship Award designed to support people with metabolic disorders, such as Phenylketonuria (PKU), accessing further education, training and development courses or apprenticeships.
Entrants [...]
Galen Announces Completion of Multi-Million Pound POA Pharma Acquisition
07 Jan 2020
Move adds substantial new therapeutic areas and territories to Galen’s reach
Craigavon, N.I., 8 Jan 2020 - Galen, the privately owned global pharmaceutical sales and marketing company, today announced the completion of a multi-million pound acquisition and takeover of boutique healthcare company, POA Pharma. The move enables Galen to significantly expand its global reach and...